Pharmaceutical Technology will feature video coverage of AAPS this month.
Like many readers of Pharmaceutical Technology, I will be attending the annual meeting and exhibition of the American Association of Pharmaceutical Scientists (AAPS) in Atlanta, on Nov. 16–20. AAPS always provides a great opportunity to hear the leading minds in the pharmaceutical sciences, and PharmTech will be building on that tradition through a new project that we are launching at AAPS.
Patricia Van Arnum
Michelle Hoffman, editor-in-chief, Maribel Rios, senior editor, and I will interview session speakers and other industry thought leaders live at the PharmTech booth (Number 1331). These interviews will make up our Vidcast program, which will be posted here and delivered in special AAPS editions of ePT,Pharmaceutical Technology's weekly electronic newsletter.
Moheb Nasr, director of FDA's Office of New Drug Quality Assessment, will discuss FDA's quality-by-design (QbD) initiative as it applies to analytical methods. Excipient manufacturers will offer their views on QbD and how to achieve better process understanding.
Experts will also explain the potential of liquid-filled hard capsules, including their use in early clinical studies as a quick-to-market option, and the promise of nanotechnology in drug delivery. Industry leaders will discuss the fundamentals of particles and powders and the characteristics needed to produce a quality solid dosage form. Speakers will also explain how approaches such as hot-melt extrusion, nanocrystals, and spray-dried solid dispersions can overcome poor solubility. And AAPS President Karen Habucky will share her views on education for pharmaceutical scientists and engineers.
So tune in here for the latest from AAPS.
Patricia Van Arnum is a senior editor of Pharmaceutical Technology.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.